Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products gain traction. …